Displaying publications 21 - 27 of 27 in total

Abstract:
Sort:
  1. Elevated serum lipoprotein(A) concentrations in different sub-groups of clinical familial hypercholesterolaemia and their unaffected family members
    Rahmat R, Chua YA, Ismail Z, Mohd Kasim NA, Abdul Rahman T, Ramli AS, et al.
    Atherosclerosis, 2017 Aug;263:e60.
    PMID: 29366167 DOI: 10.1016/j.atherosclerosis.2017.06.202
  2. Coronary risk biomarkers in centrally obese subjects with and without metabolic syndrome
    Safura Ramli A, Osman MT, Nasir NM, Saimin H, Abdul Rahman TH, Abdul Razak S, et al.
    Atherosclerosis, 2017 Aug;263:e265-e267.
    PMID: 29366009 DOI: 10.1016/j.atherosclerosis.2017.06.860
  3. Ficus deltoidea reduces expression of interleukin 6 via nuclear factor kappa b pathway in human coronary artery endothelial cells
    Muid S, Omar E, Ikhsan Ahmad R, Hadiani Ismail N, Alicezah Mohd Kasim N, Manaf Ali A, et al.
    Atherosclerosis, 2017 Aug;263:e122.
    PMID: 29365500 DOI: 10.1016/j.atherosclerosis.2017.06.392
  4. C-reactive protein is highly expressed in visceral adipose tissue of obese but not lean subjects: A post mortem study
    Noorjamal NA, Omar E, Kaur M, Shah Mahmood M, Hasmi AH, Nawawi HM
    Atherosclerosis, 2017 Aug;263:e122.
    PMID: 29365498 DOI: 10.1016/j.atherosclerosis.2017.06.393
  5. Statin naive patients during acute coronary syndrome in Malaysia
    Chua NYC, Chong PF, Najme Khir R, Lim CW, Ismail JR, Mohd Arshad MK, et al.
    Atherosclerosis, 2017 Aug;263:e184.
    PMID: 29365712 DOI: 10.1016/j.atherosclerosis.2017.06.591
  6. Ficus deltoidea Trengganuensis is the most potent variant in reducing endothelial activation and monocyte-endothelial cell interaction in stimulated human coronary artery endothelial cells
    Muid S, Omar E, Ahmad RI, Ismail NH, Mohd Kasim NA, Ali AM, et al.
    Atherosclerosis, 2017 Aug;263:e135-e136.
    PMID: 29365540 DOI: 10.1016/j.atherosclerosis.2017.06.433
  7. Fulltext Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank
    Welsh P, Al Zabiby A, Byrne H, Benbow HR, Itani T, Farries G, et al.
    Atherosclerosis, 2024 Feb;389:117437.
    PMID: 38219651 DOI: 10.1016/j.atherosclerosis.2023.117437
    BACKGROUND AND AIMS: Elevated lipoprotein(a) [Lp(a)] is a genetic driver for atherosclerotic cardiovascular disease (ASCVD). We aimed to provide novel insights into the associated risk of elevated versus normal Lp(a) levels on major adverse cardiovascular events (MACE) in an incident ASCVD cohort.

    METHODS: This was an observational cohort study of incident ASCVD patients. MACE counts and incidence rates (IRs) per 100-person-years were reported for patients with normal (<65 nmol/L) and elevated (>150 nmol/L) Lp(a) within the first year after incident ASCVD diagnosis and overall follow-up. Cox proportional hazard models quantified the risk of MACE associated with a 100 nmol/L increase in Lp(a).

    RESULTS: The study cohort included 32,537 incident ASCVD patients; 5204 with elevated and 22,257 with normal Lp(a). Of those with elevated Lp(a), 41.2% had a subsequent MACE, versus 35.61% with normal Lp(a). Within the first year of follow-up, the IRs of composite MACE and coronary revascularisation were significantly higher (p < 0.001) in patients with elevated versus normal Lp(a) (IR difference 6.79 and 4.66). This trend was also observed in the overall follow-up (median 4.7 years). Using time to first subsequent MACE, a 100 nmol/L increase in Lp(a) was associated with an 8.0% increased risk of composite MACE, and 18.6% increased risk of coronary revascularisation during the overall follow-up period.

    CONCLUSIONS: The association of elevated Lp(a) with increased risk of subsequent MACE and coronary revascularisation highlights a population who may benefit from earlier and more targeted intervention for cardiovascular risk including Lp(a), particularly within the first year after ASCVD diagnosis. Proactive Lp(a) testing as part of routine clinical practice can help identify and better manage these higher-risk individuals.

Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links